Microenvironmental Impact In The Treatment Of Acute Lymphoblastic Leukemia
Funder
National Health and Medical Research Council
Funding Amount
$621,458.00
Summary
Acute lymphoblastic leukemia remains one of the leading causes of death in children and outcomes for adults with this disease remain poor. This project examines how manipulation of the environment where leukemia arises can be used to therpaeutic advancage. Acute lymphoblastic leukemia cells are highly dependent on the support provided by bone marrow cells but the mechanisms are not well understood. Disrupting signals from the bone marrow cells has potential as a therapeutic strategy.
A Clinical Trial Of Partially HLA-matched Unrelated Donor Microtransplantation For Prevention Of Relapse In Patients With Acute Myeloid Leukaemia Ineligible For Standard Haemopoietic Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$154,828.00
Summary
Acute myeloid leukaemia has a poor prognosis in patients unable to undergo bone marrow transplant, in particular in the elderly. No proven therapy improves their poor outcome. There is an urgent need to identify clinically applicable, non-toxic therapies for this group of patients. We will perform a clinical trial of "microtransplantation" using unrelated stem cell donors in combination with chemotherapy to try to reduce the relapse rate in these patients without the toxic effects of standard st ....Acute myeloid leukaemia has a poor prognosis in patients unable to undergo bone marrow transplant, in particular in the elderly. No proven therapy improves their poor outcome. There is an urgent need to identify clinically applicable, non-toxic therapies for this group of patients. We will perform a clinical trial of "microtransplantation" using unrelated stem cell donors in combination with chemotherapy to try to reduce the relapse rate in these patients without the toxic effects of standard stem cell transplantation.Read moreRead less
Niche Regulation Of Normal And Malignant Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$622,655.00
Summary
Hematopoietic stem cells (HSC) reside in the bone marrow (BM) and make all the cells of the blood system. We study molecules in the BM regulating normal HSC to helping them survive chemotherapy. This means cancer patients should suffer less side-effects from their therapy. Some of these molecule also help leukaemia stem cells (LSC) resist chemotherapy. Inhibitors may a) reduce patient mortality caused by chemotherapy and b) sensitise LSC to chemotherapy enabling long-term cure.